$3440 | Single User
$5910 | Enterprise License

Diabetes Therapeutics Market by Product
[Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and
[Report Updated: 01-08-2017]

Published by Allied Market Research: 01 Aug 2017 | 123323 | In Stock
Related Topics: AstraZeneca , Biotechnology , Boehringer Ingelheim , Diabetes , GlaxoSmithKline , Lilly , Novartis , Pfizer

Introduction

The global diabetes therapeutics market was valued at ,993 million in 2016, and is estimated to reach 6,842 million by 2023, growing at a CAGR of 16.0% from 2017 to 2023. Diabetes therapeutics are drugs used by diabetic patients to restore the blood glucose metabolism to a normal state.

The factors that drive the global diabetes therapeutics market include rise in geriatric population, increase in prevalence of diabetes worldwide, sedentary lifestyle of people, development of affordable & effective diabetes therapeutics, growth in awareness among people about self-management of diabetes, and support from the government However, side effects of diabetic drugs and stringent approval process for the same restrict the market growth. Moreover, surge in awareness about diabetes care and market potential in developing regions are expected to provide numerous opportunities for market growth.

The global diabetes therapeutics market is segmented on the basis of product and region. Based on product, it is bifurcated into injectable and oral-antidiabetic drugs (OAD). Injectable are further categorized into insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, and amylinomimetic drug. Oral-antidiabetic drugs (OAD) segment is further divided into biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, meglitinides, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market with current trends and future estimations from 2016 to 2023 to elucidate the imminent investment pockets.

Comprehensive analysis of factors that drive and restrict the growth of the market is provided.

Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.

Key market players are profiled and their strategies are analyzed thoroughly, which help understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

BY PRODUCT

Injectables

Insulin

Glucagon-like Peptide-1 (GLP-1) Receptor Agonists/Incretin Mimetics

Amylin Analogue/Amylinomimetic Drugs

Oral-antidiabetic Drugs (OAD)

Biguanides

Sulfonylureas

Thiazolidinediones

Alpha-glucosidase Inhibitors

Dipeptidyl Peptidase IV (DPP-4) Inhibitors/Gliptins

Meglitinides

Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors/Gliflozins

BY REGION

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

AstraZeneca plc

Boehringer Ingelheim GmbH

Eli Lilly and Company

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co., Inc.

Novartis AG

Novo Nordisk

Sanofi S.A.

Takeda Pharmaceutical Company Limited

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)

Astellas Pharma Inc.

Biocon Limited

Diasome Pharmaceuticals, Inc.

Generex Biotechnology Corp.

MannKind Corporation

Pfizer Inc.

Table of Contents
for Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and [Report Updated: 01-08-2017]

  • CHAPTER 1 INTRODUCTION

    1.1. REPORT DESCRIPTION

    1.2. KEY BENEFITS FOR STAKEHOLDERS

    1.3. KEY MARKET SEGMENTS

    1.4. RESEARCH METHODOLOGY

    1.4.1. Secondary research

    1.4.2. Primary research

    1.4.3. Analyst tools and models

    CHAPTER 2 EXECUTIVE SUMMARY

    2.1. KEY FINDINGS OF THE STUDY

    2.2. CXO PERSPECTIVE

    CHAPTER 3 MARKET OVERVIEW

    3.1. MARKET DEFINITION AND SCOPE

    3.2. KEY FINDINGS

    3.2.1. Top investment pockets

    3.2.2. Top winning strategies

    3.2.2.1. Competitive intelligence of companies and their strategies

    3.3. MARKET SHARE ANALYSIS, 2016

    3.4. MARKET DYNAMICS

    3.4.1. Drivers

    3.4.2. Restraints

    3.4.3. Opportunities

    3.4.4. Impact analysis

    3.5. CLINICAL TRIALS

    CHAPTER 4 GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT

    4.1. OVERVIEW

    4.1.1. Market size and forecast

    4.2. INJECTABLES

    4.2.1. Insulin

    4.2.1.1. Market size and forecast

    4.2.2. Glucagon-like peptide-1 (GLP-1) receptor agonists

    4.2.2.1. Market size and forecast

    4.2.3. Amylinomimetic drug

    4.2.3.1. Market size and forecast

    4.2.4. Key market trends

    4.2.5. Growth factors and opportunities

    4.2.6. Market size and forecast

    4.3. ORAL-ANTIDIABETIC DRUGS (OAD)

    4.3.1. Biguanides

    4.3.1.1. Market size and forecast

    4.3.2. Sulfonylureas

    4.3.2.1. Market size and forecast

    4.3.3. Thiazolidinediones

    4.3.3.1. Market size and forecast

    4.3.4. Alpha-glucosidase inhibitors

    4.3.4.1. Market size and forecast

    4.3.5. Dipeptidyl Peptidase IV (DPP-4) inhibitors

    4.3.5.1. Market size and forecast

    4.3.6. Meglitinides

    4.3.6.1. Market size and forecast

    4.3.7. Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

    4.3.7.1. Market size and forecast

    4.3.8. Key market trends

    4.3.9. Growth factors and opportunities

    4.3.10. Market size and forecast

    CHAPTER 5 DIABETES THERAPEUTICS MARKET, BY REGION

    5.1. OVERVIEW

    5.1.1. Market size and forecast

    5.2. NORTH AMERICA

    5.2.1. Key market trends

    5.2.2. Key growth factors and opportunities

    5.2.3. Market size and forecast

    5.2.4. U.S.

    5.2.5. Canada

    5.2.6. Mexico

    5.3. EUROPE

    5.3.1. Key market trends

    5.3.2. Key growth factors and opportunities

    5.3.3. Market size and forecast

    5.3.4. Germany

    5.3.5. France

    5.3.6. UK

    5.3.7. Italy

    5.3.8. Spain

    5.3.9. Rest of Europe

    5.4. ASIA-PACIFIC

    5.4.1. Key market trends

    5.4.2. Key growth factors and opportunities

    5.4.3. Market size and forecast

    5.4.4. Japan

    5.4.5. China

    5.4.6. India

    5.4.7. Australia

    5.4.8. South Korea

    5.4.9. Rest of Asia-Pacific

    5.5. LAMEA

    5.5.1. Key market trends

    5.5.2. Key growth factors and opportunities

    5.5.3. Market size and forecast

    5.5.4. Brazil

    5.5.5. South Africa

    5.5.6. Saudi Arabia

    5.5.7. Rest of LAMEA

    CHAPTER 6 COMPANY PROFILES

    6.1. ASTRAZENECA PLC

    6.1.1. Company overview

    6.1.2. Operating business segments

    6.1.3. Business performance

    6.1.4. Key strategic moves and developments

    6.2. BOEHRINGER INGELHEIM GMBH

    6.2.1. Company overview

    6.2.2. Operating business segments

    6.2.3. Business performance

    6.2.4. Key strategic moves and developments

    6.3. ELI LILLY AND COMPANY

    6.3.1. Company overview

    6.3.2. Operating business segments

    6.3.3. Key strategic moves and developments

    6.4. GLAXOSMITHKLINE PLC

    6.4.1. Company overview

    6.4.2. Operating business segments

    6.4.3. Business performance

    6.4.4. Key strategic moves and developments

    6.5. JOHNSON & JOHNSON

    6.5.1. Company overview

    6.5.2. Operating business segments

    6.5.3. Business performance

    6.5.4. Key strategic moves and developments

    6.6. MERCK & CO., INC.

    6.6.1. Company overview

    6.6.2. Operating business segments

    6.6.3. Business performance

    6.6.4. Key strategic moves and developments

    6.7. NOVARTIS AG

    6.7.1. Company overview

    6.7.2. Operating business segments

    6.7.3. Business performance

    6.7.4. Key strategic moves and developments

    6.8. NOVO NORDISK

    6.8.1. Company overview

    6.8.2. Operating business segments

    6.8.3. Business performance

    6.8.4. Key strategic moves and developments

    6.9. SANOFI S.A.

    6.9.1. Company overview

    6.9.2. Operating business segments

    6.9.3. Business performance

    6.9.4. Key strategic moves and developments

    6.10. TAKEDA PHARMACEUTICAL COMPANY LIMITED

    6.10.1. Company overview

    6.10.2. Operating business segments

    6.10.3. Business performance

    6.10.4. Key strategic moves and developments

List Of Tables
in Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and [Report Updated: 01-08-2017]

TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)

TABLE 2. GLOBAL INJECTABLE DIABETES THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 3. DIABETES INJECTABLE THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 4. GLOBAL OAD DIABETES THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)

TABLE 5. GLOBAL OAD DIABETES THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)

TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)

TABLE 9. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 10. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)

TABLE 11. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 12. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)

TABLE 13. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)

TABLE 14. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2016-2023 ($MILLION)

TABLE 15. ASTRAZENECA: COMPANY SNAPSHOT

TABLE 16. BOEHRINGER: COMPANY SNAPSHOT

TABLE 17. ELI LILLY: COMPANY SNAPSHOT

TABLE 18. GLAXOSMITHKLINE: COMPANY SNAPSHOT

TABLE 19. J&J: COMPANY SNAPSHOT

TABLE 20. MERCK: COMPANY SNAPSHOT

TABLE 21. NOVARTIS: COMPANY SNAPSHOT

TABLE 22. NOVO NORDISK: COMPANY SNAPSHOT

TABLE 23. SANOFI: COMPANY SNAPSHOT

TABLE 24. TAKEDA: COMPANY SNAPSHOT

List Of Figures, Charts and Diagrams
in Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and [Report Updated: 01-08-2017]

FIGURE 1. DIABETES THERAPEUTICS MARKET SEGMENTATION

FIGURE 2. TOP INVESTMENT POCKETS

FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2014-2016)

FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE

FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES

FIGURE 6. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES

FIGURE 7. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES

FIGURE 8. MARKET SHARE ANALYSIS, DIABETES THERAPEUTICS MARKET, 2016

FIGURE 9. IMPACT ANALYSIS: DIABETES THERAPEUTICS MARKET

FIGURE 10. TOTAL NUMBER OF CLINICAL TRIALS IN DIABETES THERAPEUTICS MARKET

FIGURE 11. INSULIN MARKET, 2016-2023, ($MILLION)

FIGURE 12. GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS/INCRETIN MIMETICS MARKET, 2016-2023, ($MILLION)

FIGURE 13. AMYLIN ANALOGUE/AMYLINOMIMETIC DRUG MARKET, 2016-2023, ($MILLION)

FIGURE 14. BIGUANIDES MARKET, 2016-2023, ($MILLION)

FIGURE 15. SULFONYLUREAS MARKET, 2016-2023, ($MILLION)

FIGURE 16. THIAZOLIDINEDIONES MARKET, 2016-2023, ($MILLION)

FIGURE 17. ALPHA-GLUCOSIDASE INHIBITORS MARKET, 2016-2023, ($MILLION)

FIGURE 18. DIPEPTIDYL PEPTIDASE IV (DPP-4) INHIBITORS /GLIPTINS MARKET, 2016-2023, ($MILLION)

FIGURE 19. MEGLITINIDES MARKET, 2016-2023, ($MILLION)

FIGURE 20. SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS /GLIFLOZINS MARKET, 2016-2023, ($MILLION)

FIGURE 21. U.S. DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 22. CANADA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 23. MEXICO DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 24. GERMANY DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 25. FRANCE DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 26. UK DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 27. ITALY DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 28. SPAIN DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 29. REST OF EUROPE DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 30. JAPAN DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 31. CHINA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 32. INDIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 33. AUSTRALIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 34. SOUTH KOREA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 35. REST OF ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 36. BRAZIL DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 37. SOUTH AFRICA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 38. SAUDI ARABIA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

FIGURE 39. REST OF LAMEA DIABETES THERAPEUTICS MARKET, 2016-2023, ($MILLION)

Additional Details

Publisher

Allied Market Research

Publisher Information

Reference

123323 | LI 173542

Number of Pages

170

Report Format

PDF

Allied Market Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (US)
IntroductionWhat environmental market barriers are influencing the Type 2 Diabetes (T2DM) market? F...
20 Apr 2015 by FirstWord Pharma USD $4,995 More Info
FirstView Barriers – An Analysis of Market Barriers in Type 2 Diabetes (EU5)
IntroductionWhat market barriers are influencing the Type 2 Diabetes (T2DM) market? From price to a...
20 Apr 2015 by FirstWord Pharma USD $4,995 More Info
Physician Views: How do endocrinologists value diabetes-focused medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
08 Dec 2014 by FirstWord Pharma USD $695 More Info
Physician Views: US formulary management in diabetes – are endocrinologists impressed?
Scope Pricing pressure exerted by US pharmacy benefit managers (PBMs) and managed care organisations...
12 Aug 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Five key diabetes market questions ahead of ADA 2014
Scope This year's annual meeting of the American Diabetes Association (ADA) – which will take place ...
13 Jun 2014 by FirstWord Pharma USD $695 More Info
Diabetes -- KOL Insight and Consensus Outlook Modules
IntroductionThe medium term: battle lines are drawnThe fundamental drivers of the global diabetes ma...
01 May 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: Which diabetes company does the best marketing job? What is key for companies launching products?
ScopeThe importance of marketing is increasingly coming to the fore as diabetes-focused companies ba...
01 Aug 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Post ADA view on key diabetes market developments
ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
01 Jul 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
01 Jul 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
01 Jun 2013 by FirstWord Pharma USD $695 More Info

This report is published by Allied Market Research

Download Free Report Summary PDF

Diabetes Therapeutics Market by Product [Injectables (Insulin, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, and Amylinomimetic Drugs) and Oral-antidiabetic Drugs (OAD) (Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase Inhibitors, Dipeptidyl Peptidase IV (DPP-4) Inhibitors, Meglitinides, and Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors)] - Global Opportunity Analysis and  [Report Updated: 01-08-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...